Comprehensive Gene Mutation Profiling of Circulating Tumor DNA in Ovarian Cancer: Its Pathological and Prognostic Impact
Open Access
- 16 November 2020
- Vol. 12 (11), 3382
- https://doi.org/10.3390/cancers12113382
Abstract
Liquid biopsies from circulating tumor DNA (ctDNA) have been employed recently as a non-invasive diagnostic tool for detecting cancer-specific gene mutations. Here, we show the comprehensive gene mutation profiles of ctDNA in 51 patients with different histological subtypes of stage I–IV ovarian cancer, and their association with clinical outcomes. The ctDNA extracted from pre-treatment patients’ plasma were analyzed using Cancer Personalized Profiling by Deep Sequencing targeting 197 genes. Of 51 patients, 48 (94%) showed one or more non-synonymous somatic mutations, including TP53 (37.3%), APC (17.6%), KRAS (15.7%), EGFR (13.7%), MET (11.8%), PIK3CA (11.8%), NPAP1 (11.8%), and ALK (9.8%). The most frequently mutated genes were as follows: TP53 in high-grade serous carcinoma (66.7%), APC in clear cell carcinoma (30.8%), PIK3CA in endometrioid carcinoma (40%), and KRAS in mucinous carcinoma (66.7%). Higher cell-free (cf)DNA concentration significantly correlated with worse progression-free survival (PFS) in all patients as well as stage III–IV patients (p = 0.01 and 0.005, respectively). Further, patients with any pathogenic mutations showed significantly worse PFS (p = 0.048). Blood tumor mutational burden detected from ctDNA did not significantly correlate with the histological subtypes or survival. Collectively, clinico-genomic profiles of individual ovarian cancer patients could be identified using ctDNA and may serve as a useful prognostic indicator. These findings suggest that ctDNA-based gene profiling might help in establishing personalized therapeutic strategies.Keywords
This publication has 57 references indexed in Scilit:
- Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal CancerClinical Cancer Research, 2013
- Cancer statistics, 2013CA: A Cancer Journal for Clinicians, 2013
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian CancerThe New England Journal of Medicine, 2011
- Integrated genomic analyses of ovarian carcinomaNature, 2011
- Cell-free nucleic acids as biomarkers in cancer patientsNature Reviews Cancer, 2011
- Genomics and the Continuum of Cancer CareThe New England Journal of Medicine, 2011
- Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimusJCI Insight, 2010
- Frequent Activating Mutations of PIK3CA in Ovarian Clear Cell CarcinomaThe American Journal of Pathology, 2009
- Prognostic significance of p53 mutation in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatinCancer Letters, 2006
- Future options for first-line therapy of advanced ovarian cancerInternational Journal of Gynecologic Cancer, 2005